Cisplatin-associated neurotoxicity: Can it be prevented?

David S Alberts, J. K. Noel

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Neurotoxicity remains the major dose-limiting toxicity of cisplatin. Peripheral sensory neuropathy, the primary type of cisplatin neurotoxicity, has been reported in 30-100% of patients with clinical symptoms typically developing after cumulative cisplatin doses of ≥ 300 mg/m2. Several clinical studies have established an important dose-response, dose intensity-response and cumulative total dose-response relationship for cisplatin in the treatment of head and neck, testicular, melanoma, and ovarian cancers. In patients with these tumor types, the occurrence of moderate or severe neuropathy presents an important therapeutic dilemma. Several types of agents - including micleophilic sulfur thiols, neurotrophic factors, phosphonic acid antibiotics and free oxygen radical scavengers - have been investigated for amelioration of cisplatin-related neurotoxicity. Of these, amifostine is likely to be the first neuroprotective agent widely used to enhance the clinical effectiveness of cisplatin. Recently reported results from a multicenter phase III trial of women with advance ovarian cancer receiving combination chemotheraphy with cisplatin plus cyclophosphamide showed that amifostine pretreatment was associated with moderate but significant reductions in cisplatin-associated peripheral neuropathy, tinnitus and nephrotoxicity, while achieving equivalent pathological response rates and median survival. Preclinical data suggest that several additional agents, especially the neurotropic factors nerve growth factor, insulin-like growth factor-I and neurotrophin-3, merit further investigation. Nerve growth factor is the only agent reported to prevent, rather than partially protect, cisplatin-induced neuropathy in an experimental model.

Original languageEnglish (US)
Pages (from-to)369-383
Number of pages15
JournalAnti-Cancer Drugs
Volume6
Issue number3
StatePublished - 1995

Fingerprint

Cisplatin
Amifostine
Peripheral Nervous System Diseases
Nerve Growth Factor
Ovarian Neoplasms
Neurotrophin 3
Free Radical Scavengers
Tinnitus
Testicular Neoplasms
Nerve Growth Factors
Neuroprotective Agents
Insulin-Like Growth Factor I
Sulfur
Sulfhydryl Compounds
Cyclophosphamide
Melanoma
Reactive Oxygen Species
Theoretical Models
Neck
Survival Rate

Keywords

  • cisplatin
  • neurotoxicity
  • prevention

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Cisplatin-associated neurotoxicity : Can it be prevented? / Alberts, David S; Noel, J. K.

In: Anti-Cancer Drugs, Vol. 6, No. 3, 1995, p. 369-383.

Research output: Contribution to journalArticle

@article{ab6fbc4e67d74cfc939719af27f224c4,
title = "Cisplatin-associated neurotoxicity: Can it be prevented?",
abstract = "Neurotoxicity remains the major dose-limiting toxicity of cisplatin. Peripheral sensory neuropathy, the primary type of cisplatin neurotoxicity, has been reported in 30-100{\%} of patients with clinical symptoms typically developing after cumulative cisplatin doses of ≥ 300 mg/m2. Several clinical studies have established an important dose-response, dose intensity-response and cumulative total dose-response relationship for cisplatin in the treatment of head and neck, testicular, melanoma, and ovarian cancers. In patients with these tumor types, the occurrence of moderate or severe neuropathy presents an important therapeutic dilemma. Several types of agents - including micleophilic sulfur thiols, neurotrophic factors, phosphonic acid antibiotics and free oxygen radical scavengers - have been investigated for amelioration of cisplatin-related neurotoxicity. Of these, amifostine is likely to be the first neuroprotective agent widely used to enhance the clinical effectiveness of cisplatin. Recently reported results from a multicenter phase III trial of women with advance ovarian cancer receiving combination chemotheraphy with cisplatin plus cyclophosphamide showed that amifostine pretreatment was associated with moderate but significant reductions in cisplatin-associated peripheral neuropathy, tinnitus and nephrotoxicity, while achieving equivalent pathological response rates and median survival. Preclinical data suggest that several additional agents, especially the neurotropic factors nerve growth factor, insulin-like growth factor-I and neurotrophin-3, merit further investigation. Nerve growth factor is the only agent reported to prevent, rather than partially protect, cisplatin-induced neuropathy in an experimental model.",
keywords = "cisplatin, neurotoxicity, prevention",
author = "Alberts, {David S} and Noel, {J. K.}",
year = "1995",
language = "English (US)",
volume = "6",
pages = "369--383",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cisplatin-associated neurotoxicity

T2 - Can it be prevented?

AU - Alberts, David S

AU - Noel, J. K.

PY - 1995

Y1 - 1995

N2 - Neurotoxicity remains the major dose-limiting toxicity of cisplatin. Peripheral sensory neuropathy, the primary type of cisplatin neurotoxicity, has been reported in 30-100% of patients with clinical symptoms typically developing after cumulative cisplatin doses of ≥ 300 mg/m2. Several clinical studies have established an important dose-response, dose intensity-response and cumulative total dose-response relationship for cisplatin in the treatment of head and neck, testicular, melanoma, and ovarian cancers. In patients with these tumor types, the occurrence of moderate or severe neuropathy presents an important therapeutic dilemma. Several types of agents - including micleophilic sulfur thiols, neurotrophic factors, phosphonic acid antibiotics and free oxygen radical scavengers - have been investigated for amelioration of cisplatin-related neurotoxicity. Of these, amifostine is likely to be the first neuroprotective agent widely used to enhance the clinical effectiveness of cisplatin. Recently reported results from a multicenter phase III trial of women with advance ovarian cancer receiving combination chemotheraphy with cisplatin plus cyclophosphamide showed that amifostine pretreatment was associated with moderate but significant reductions in cisplatin-associated peripheral neuropathy, tinnitus and nephrotoxicity, while achieving equivalent pathological response rates and median survival. Preclinical data suggest that several additional agents, especially the neurotropic factors nerve growth factor, insulin-like growth factor-I and neurotrophin-3, merit further investigation. Nerve growth factor is the only agent reported to prevent, rather than partially protect, cisplatin-induced neuropathy in an experimental model.

AB - Neurotoxicity remains the major dose-limiting toxicity of cisplatin. Peripheral sensory neuropathy, the primary type of cisplatin neurotoxicity, has been reported in 30-100% of patients with clinical symptoms typically developing after cumulative cisplatin doses of ≥ 300 mg/m2. Several clinical studies have established an important dose-response, dose intensity-response and cumulative total dose-response relationship for cisplatin in the treatment of head and neck, testicular, melanoma, and ovarian cancers. In patients with these tumor types, the occurrence of moderate or severe neuropathy presents an important therapeutic dilemma. Several types of agents - including micleophilic sulfur thiols, neurotrophic factors, phosphonic acid antibiotics and free oxygen radical scavengers - have been investigated for amelioration of cisplatin-related neurotoxicity. Of these, amifostine is likely to be the first neuroprotective agent widely used to enhance the clinical effectiveness of cisplatin. Recently reported results from a multicenter phase III trial of women with advance ovarian cancer receiving combination chemotheraphy with cisplatin plus cyclophosphamide showed that amifostine pretreatment was associated with moderate but significant reductions in cisplatin-associated peripheral neuropathy, tinnitus and nephrotoxicity, while achieving equivalent pathological response rates and median survival. Preclinical data suggest that several additional agents, especially the neurotropic factors nerve growth factor, insulin-like growth factor-I and neurotrophin-3, merit further investigation. Nerve growth factor is the only agent reported to prevent, rather than partially protect, cisplatin-induced neuropathy in an experimental model.

KW - cisplatin

KW - neurotoxicity

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=0029044882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029044882&partnerID=8YFLogxK

M3 - Article

C2 - 7670134

AN - SCOPUS:0029044882

VL - 6

SP - 369

EP - 383

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 3

ER -